Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
20 nov 2015 - 07:38
Statutaire naam
Galapagos NV
Titel
Galapagos initiates Phase 1 First-in-Human study with GLPG1972, receives €3.5 million milestone from Servier
Bericht
Mechelen, Belgium; 20 November 2015 - Galapagos NV (Euronext & NASDAQ: GLPG) announced today that GLPG1972, a first-in-class candidate drug aiming at treating osteoarthritis, has been dosed in a Phase 1 First-in-Human study. GLPG1972 has a novel mode of action discovered by Galapagos under its collaboration agreement with Servier, and has potential application in osteoarthritis. Galapagos will receive a €3.5 million milestone payment from Servier for this achievement.
Gerelateerde downloads
Datum laatste update: 15 december 2025